Hear Drew Weissman, MD, PhD, on the Giants of Gene Therapy Podcast

Yuliya Klochan, MSJ - March 07, 2023

Drew Weissman, MD, PhD, a 2023 Nobel Prize laureate, shared his personal journey and ups and downs of pioneering mRNA vaccines now used for COVID, HIV, food allergies, and more. ASGCT President Hans-Peter Kiem, MD, PhD, hosted the one-on-one conversation in the fourth episode of ASGCT’s Giants of Gene Therapy.

Drew Weissman, MD, PhD, is the Roberts Family Professor in Vaccine Research, Director of Vaccine Research in the Infectious Diseases Division, and Director of the Institute for RNA Innovation at the University of Pennsylvania. He co-created the nucleoside-modified mRNA technology and other mRNA vaccine-related improvements, patented in 2005.  

Dr. Weissman’s inventions have been used in more than a billion administered doses of the Pfizer and Moderna COVID-19 vaccines. They have the potential to address a range of medical conditions. Dr. Weissman is now working on pan-coronavirus, universal flu, HIV, food allergy, and herpes vaccines, as well as mRNA cancer therapeutics. He’s promoting global vaccine access by working with governments and universities around the world, while combating vaccine hesitancy.  

Dr. Weissman has received numerous awards and honors, including the 2023 Nobel Prize in Physiology or Medicine (co-received with Katalin Karikó, PhD). He has been an ASGCT member and Annual Meeting keynote speaker. 

During his one-on-one conversation with ASGCT President Hans-Peter Kiem, MD, PhD, Dr. Weissman shared his personal journey and ups and downs of pioneering mRNA vaccines now used for COVID, HIV, food allergies, and more.

You can subscribe to the ASGCT channel wherever you listen to your podcasts (including AppleSpotify, Overcast, Pocket Casts, and more).

Search “ASGCT” in your podcast app to subscribe to the ASGCT Podcast Network

Music by: Steven O'Brien

"Making Progress"

(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)


Yuliya Klochan, MSJ, is ASGCT's senior communications manager

Related Articles


Targeting STAT3 in Tumors with Oligo-PROTAC with Dr. Marcin Kortylewski

Listen to this episode of The Molecular Therapy Podcast - July 09, 2024
Molecular Therapy

AAV Capsid Production with Drs. Mario Mietzsch and Robert McKenna

Molecular Therapy Podcast - June 18, 2024

Gene Insertion Tech with SalioGen CEO Jason Cole

ASGCT Podcast Network - June 11, 2024
Molecular Therapy

A New Vision for MTMCD with EiC Dr. Mohamed Abou-el-Enein

ASGCT Podcast Network - June 04, 2024